Skip to main content
. 2021 Oct 1;20:15330338211042139. doi: 10.1177/15330338211042139

Table 1.

Patient baseline characteristics prior to initiation of liposomal doxorubicin. (no. = number of patients, FOLFIRINOX = folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; 5-FU = 5-fluorouracil).

Patient characteristics Absolute number of patients Percentage of patients (%)
Total number of patients 28 100%
Age (years)
 Median 67.5 years
 Range 46 to 89 years
Sex (no.)
 Male 13 46%
 Female 15 54%
Prior palliative lines (no.)
 FOLFIRINOX 18 64%
 Gemcitabine /nab-Paclitaxel 23 82%
 Gemcitabine mono (± experimental antibody) 4 14%
Nal-Irinotecan/5-FU 3 11%
Liposomal doxorubicin as palliative chemotherapy (no.)
 2nd line 5 18%
 3rd line 18 64%
 4th line 4 14%
 5th line 1 4%
Metastasis at start of liposomal doxorubicin (no.)
 Hepatal 18 64%
 Pulmonary 8 29%
 Peritoneal 5 18%
 Bone 1 4%
 Adrenal 1 4%
 metastases in ≥ 1 organ 6 21%